CHOP+美罗华方案治疗B细胞非霍奇金淋巴瘤6例临床观察

Combination of CHOP and Rituximab for B cell non-Hodgkin's lymphoma(six cases report)

目的观察CHOP＋美罗华初治和复治B细胞非霍奇金淋巴瘤的疗效。方法6例患者均经病理组织学证实为CD20阳性的B细胞非霍奇金淋巴瘤。2例为初治者，4例为复发难治者，CHOP按标准方案，共6～8疗程。美罗华375mg／m^2，静脉滴注，1次／周，共4周为1疗程。结果完全缓解4例，部分缓解1例，无效1例，有效率为83％。随访时间2～6年，除1例无效死亡，其余保持完全缓解或部分缓解。结论美罗华对CD20阳性的B细胞非霍奇金淋巴瘤疗效肯定，尤其在清除微小残余病灶、减少复发方面疗效显著。

Objective To investigate the effectiveness of CHOP and Rituximab for B cell non-Hodgkin＇s lymphoma （NHL）, in either untreated or relapsed patients. Methods Six patients with histologically documented CD20 （＋） B-cell lymphoma were included. Among them, two were previously untreated, and four refractory and recurrent. All were treated with standard CHOP chemotherapy for 6-8 cycles. Rituximab （375 mg/m^2） was intravenous infused weekly for four weeks. Results Four cases achieved complete remission （CR）, one case partial remission （PR） and one case did not respond （NR）. The overall response rate was 83 %. These patients had been followed up for 2-6 years. They remained CR or PR except one who was NR and died. Condusion Rituximab is highly effective in patients with CD20 （＋） B-cell lymphoma, especially for eradicating minimal residual disease and reducing relapse.